Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9

You may also be interested in...



LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma

SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences

LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma

SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences

Vaccine Market Will Lead Pharmaceutical Industry In China And Globally, Frost & Sullivan Predicts

SHANGHAI - The compound annual growth rate of the global pharmaceutical industry is expected to be around 4-5 percent in the next seven years, while the worldwide vaccine market grows faster, at a CAGR of 14-15 percent, the global business research and consulting firm Frost & Sullivan predicted

Related Content

UsernamePublicRestriction

Register

SC071366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel